| Prev Close: | 262.42 |
|---|---|
| Open: | 258.95 |
| Bid: | 102.59 x 200 |
| Ask: | N/A |
| 1y Target Est: | 287.06 |
| Beta: | 0.84 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 245.52 - 260.47 |
|---|---|
| 52wk Range: | 107.31 - 283.99 |
| Volume: | 855,134 |
| Avg Vol (3m): | 1,107,680 |
| Market Cap: | 24.69B |
| P/E (ttm): | 34.08 |
| EPS (ttm): | 7.48 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Today’s 3 Worst Stocksat Motley Fool(Thu May 23)
- Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggardat TheStreet(Thu May 23)
- Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8%at Forbes(Thu May 23)
- Amgen Stock Checkup for Mayat Motley Fool(Thu May 23)
- Applied Materials CEO Sells 300K Shares and 4 Insider Sales to Noteat Wall St. Cheat Sheet(Thu May 23)
- Is This Momentum Stock’s Rally Over?at Motley Fool(Wed May 22)
- Sanofi/REGN's Dupilumab Data PublishedZacks(Wed May 22)
- Regeneron Shareholders Watching Optina Trial Closelyat Seeking Alpha(Wed May 22)
- Regeneron moves higher on asthma drug study dataAP(Wed May 22)
- Stocks Stage Broad Advance; Bristol-Myers Leads Medicalsat Investor's Business Daily(Wed May 22)
- Regeneron and Sanofi: An Unstoppable Biotech Duo?at Motley Fool(Tue May 21)
- New Drug May Help Some Asthmatics, Study Findsat New York Times(Tue May 21)
- New Asthma Drug Generates Excitement For Patients -- And Its Makerat Forbes(Tue May 21)
- InPlay: Regeneron Pharms and Sanofi and announce publication of positive Phase 2a results of dupilumab in asthma in the New England Journal of MedicineBriefing.com(Tue May 21)
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of MedicinePR Newswire(Tue May 21)
Press Releases
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of MedicinePR Newswire(Tue May 21)
- Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)PR Newswire(Wed May 15)
- Charts Tell the Tale – Technical Analysis Leads to Solid Gains - NetSuite, Regeneron PharmaceuticalsAccesswire(Fri Sep 14)
Must Read
- Sears reports bigger-than-expected loss for 1st quarterThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Gap's 1st-quarter net income rises 43 per cent on strong sales as turnaround continuesThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Ralph Lauren's 4Q profit rises 35 pct, but posts sales shortfallThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Marathon Oil: talks tied to sale of part of stake in Athabasca Oil Project have endedThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- TD Bank looking for cost savings amid continued low interest ratesThe Canadian Press(1969-12-31T18:59:59GMT-05:00)